Single Technology Appraisal (STA)

Vortioxetine for treating major depressive disorder [ID583]

Comments from Servier Laboratories Limited on the Appraisal consultation document

1. Overall Servier's view is that general the document is balanced and fair in its assessment.

2. Point 3.29 "The ERG considered that Llorca may represent the most reliable evidence for comparing vortioxetine with other treatments."

- Servier acknowledge this may be true, however wish to highlight that Taylor 2014 is another non-industry sponsored meta-analysis which provides a relevant assessment of the efficacy of agomelatine compared to other comparators in the current appraisal (ID583).

  Reference: Taylor D, Sparshatt A, Varma s, Olofinjana 0. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ 2014; 348:g1888